---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000054"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:11:22.657422+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025

## Summary
- Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.
- GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.
- FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.
- UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.
- GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K.

## SEC filing metadata
- accession: 0000899923-24-000054
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/0000899923-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/mygn-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000054
- JSON: https://secwatch.observer/filing/0000899923-24-000054.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.